祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中2025年第三季度，公司单季度主 营收入1.07亿元，同比下降6.68%；单季度归母净利润2422.41万元，同比上升41.95%；单季度扣非净利 润2314.06万元，同比上升53.63%；负债率11.24%，投资收益301.23万元，财务费用-1652.62万元，毛利 率59.82%。祥生医疗（688358）主营业务：超声医学影像设备的研发、制造和销售,为国内外医疗机 构、科研机构、战略合作伙伴等提供各类超声医学影像设备和专业的技术开发服务。 该股最近90天内共有3家机构给出评级，买入评级3家。 证券之星消息，截至2026年1月30日收盘，祥生医疗(688358)报收于36.62元，上涨0.33%，换手率 1.09%，成交量1.22万手，成交额4432.57万元。 1月30日的资金流向数据方面，主力资金净流出59.79万元，占总成交额1.35%，游资资金净流出224.18 万元，占总成交额5.06%，散户资金净流入28 ...

（编辑 楚丽君） 证券日报网讯 1月30日，祥生医疗在互动平台回答投资者提问时表示，公司已布局超声人工智能技术多 年，推出的SonoAI软件在乳腺、肝脏、心血管、颈动脉、甲状腺、小器官和妇产科等方面均取得实质 性进展，核心技术已广泛搭载于高端推车彩超和便携新产品线。目前，公司暂不涉及脑机接口相关技术 研究。 ...

证券日报网讯1月30日，祥生医疗在互动平台回答投资者提问时表示，公司销售模式包括经销和直销两 种模式，经销业务为主，直销业务为辅，其中直销业务以ODM为主，面向终端的直销较少，目前公司 产品和技术已进入包括欧美市场在内的全球100多个国家和地区。 ...

格隆汇1月30日｜有投资者在互动平台向祥生医疗提问：贵公司在超声医学影像和人工智能领域深耕多 年，请问公司在超声波脑机接口方向是否有技术布局或先发优势？ 祥生医疗回复称，公司已布局超声 人工智能技术多年，推出的SonoAI软件在多个病种或临床领域，如乳腺、肝脏、心血管、颈动脉、甲 状腺、小器官和妇产科等方面均取得了实质性的进展，核心技术已经广泛搭载于高端推车彩超和便携新 产品线。目前，公司暂不涉及脑机接口相关技术研究。 ...

证券之星消息，截至2026年1月21日收盘，祥生医疗(688358)报收于38.64元，上涨5.54%，换手率 3.28%，成交量3.67万手，成交额1.41亿元。 1月21日的资金流向数据方面，主力资金净流入1259.61万元，占总成交额8.9%，游资资金净流入255.53 万元，占总成交额1.81%，散户资金净流出1515.14万元，占总成交额10.71%。 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 祥生医疗融资融券信息显示，融资方面，当日融资买入1643.49万元，融资偿还1647.52万元，融资净偿 还4.04万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量6503.0股，融券余额25.13万元。融 资融券余额1.19亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中20 ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Group 1 - The A-share market has seen a rebound in AI application concept stocks, with Shanghai Steel Union rising over 11% [1] - Other notable gainers include Jiuqi Software and Zhejiang Wenhu Internet, both hitting the 10% limit up, while Jinxi Modern and Zhongkong Technology increased by over 9% [1] - The overall trend indicates a positive momentum in the AI sector, as evidenced by the MACD golden cross signal formation [2] Group 2 - Shanghai Steel Union's market capitalization is approximately 9.791 billion, with a year-to-date increase of 22.29% [2] - Jiuqi Software has a market cap of around 8.217 billion and a year-to-date increase of 19.27% [2] - Zhejiang Wenhu Internet's market cap stands at about 16.3 billion, with a significant year-to-date increase of 40.28% [2]

Core Insights - The medical device industry is facing a "tool gap" between hardware evolution and backend service support capabilities, leading to a fusion ecosystem of "hardware + services + intelligence" as a key strategy for companies to build competitive advantages [1] - Xiangsheng Medical has launched its self-developed AI assistant application, CHISON Pilot, globally, marking a significant leap in its service support system following the smart upgrade of ultrasound mainframes [1][2] Group 1: AI Assistant CHISON Pilot - CHISON Pilot is designed to bridge the gap between advanced hardware and fragmented support services, providing real-time, precise, and personalized information integration and decision support for sales, clinical, and end-users [2] - The application is available on Google Play and Apple App Store, covering 176 countries and regions, and is not just a simple tool but a critical product aimed at enhancing service efficiency [2][3] - CHISON Pilot features three intelligent modules that deliver differentiated value in sales support, clinical assistance, and user services, evolving from a passive tool to an active AI partner that understands user preferences over time [3] Group 2: SonoAI and Intelligent Service Ecosystem - Xiangsheng Medical has established a comprehensive intelligent standard framework for ultrasound AI diagnosis, driven by a dual-engine approach of "ultrasound AI + specialized models," covering the entire process from equipment development to diagnostic decision-making [4] - The SonoAI solution has been integrated into the SonoFamily product line, enabling intelligent scanning, precise measurement, assisted diagnosis, and automated reporting across key clinical areas [4] - The company has made significant advancements in breast ultrasound AI diagnostic systems, achieving improved accuracy in BI-RADS classification and benign/malignant differentiation, supporting large-scale breast cancer screening with high sensitivity and specificity [4][5] Group 3: Strategic Implications - The continuous launch of intelligent solutions like SonoAI and CHISON Pilot is helping Xiangsheng Medical build a closed-loop intelligent ecosystem from hardware to services, enhancing product competitiveness and pushing ultrasound medicine towards standardized, replicable intelligent decision-making [5] - The company's ongoing technological innovations in AI applications are reshaping the application paradigm and value boundaries of ultrasound devices, injecting new momentum into its global market expansion [5]

Group 1 - The medical device sector increased by 0.66% on January 14, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Notable gainers in the medical device sector included Sanyou Medical, which rose by 16.63% to a closing price of 22.30, and Tianzhihang, which increased by 13.25% to 24.95 [1] Group 2 - The medical device sector experienced a net outflow of 428 million yuan from institutional investors and 495 million yuan from retail investors, while retail investors saw a net inflow of 923 million yuan [2] - The individual stock fund flow data indicated that Yuyue Medical had a net inflow of 356 million yuan from institutional investors, while it faced a net outflow of 66.06 million yuan from retail investors [3] - Other companies like Yingke Medical and Weili Medical also showed significant net inflows from institutional investors, with 105 million yuan and 90.06 million yuan respectively [3]

Core Viewpoint - Despite a decline in revenue and net profit for two consecutive years, the company has decided to implement a cash dividend, which is interpreted by the market as an effort to stabilize investor confidence [1][5]. Financial Performance - In the first three quarters of 2025, the company achieved revenue of approximately 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 105 million yuan, down 2.23% year-on-year [2][7]. - The company plans to distribute a cash dividend of 3 yuan per 10 shares (including tax), totaling 33.56 million yuan, which accounts for 35.73% of the net profit for the period [2][7]. - The accounts receivable increased significantly to 198 million yuan, a 22% rise compared to the end of the previous year, indicating a slowdown in sales collection and pressure on operating cash flow [2][6]. Strategic Projects - The company announced delays in two core fundraising projects, "Research and Innovation and Marketing Operations Base Construction" and "Innovation and Development Reserve Fund," pushing completion dates from the end of 2025 to the end of 2026 [3][8]. - As of November 2025, the investment progress for these projects was 86.39% and 77.03%, respectively, with delays attributed to uncontrollable factors in construction and quality control needs [3][8]. Governance Challenges - The current situation reflects a common governance challenge faced by many growth-oriented listed companies: balancing short-term shareholder returns with long-term development needs during periods of performance volatility [4][9]. - While the company attempts to maintain investor relations through dividends, previous disclosures of major shareholder reduction plans have impacted market sentiment, indicating a lack of solid confidence [4][9]. - The delay in fundraising projects may slow down technological upgrades and market responsiveness, increasing uncertainty in a rapidly evolving industry landscape [4][9].